论文部分内容阅读
目的观察诺和锐30与诺和灵30R治疗2型糖尿病的临床效果。方法 72例2型糖尿病患者随机分为两组,分别注射诺和灵30R和诺和锐30特充,观察患者日胰岛素总量、FBG(空腹血糖)、PBG(餐后2h血糖)、HbA1c(糖化血红蛋白)及低血糖发生率。结果两组患者治疗12周后FBG、PBG及HbA1c均能明显降低血糖至正常范围,每日胰岛素用量以诺和灵组较诺和锐组为高,有显著性差异,而低血糖发生率两组比较无统计性差异。结论两组胰岛素治疗2型糖尿病均有很好的疗效,但诺和锐30R特充相对于诺和灵30R能更有效减少日胰岛素的用量,从而降低胰岛素引起的副作用,有更好的依从性。
Objective To observe the clinical effect of Novo-Rui 30 and Noble 30R on type 2 diabetes mellitus. Methods 72 patients with type 2 diabetes mellitus were randomly divided into two groups. The patients were given Novolin 30R and Novolin Ru 30, respectively. Total daily insulin, FBG, PBG (postprandial blood glucose 2h) and HbA1c HbAlc) and the incidence of hypoglycemia. Results After 12 weeks of treatment, FBG, PBG and HbA1c in both groups significantly decreased blood glucose to the normal range. The daily insulin dosage was higher in Novo-Ling group than in Novo-Ree group, with significant difference, while the incidence of hypoglycemia was There was no statistical difference between groups. Conclusion Both groups of insulin treatment of type 2 diabetes have a good effect, but Novartis 30R refill relative to Novolin 30R can be more effective in reducing the amount of daily insulin, thereby reducing the side effects caused by insulin, have better compliance .